Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06465329 · ClinicalTrials.gov registry record · Phase 2

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT06465329: Recruiting Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals.

NCT06465329 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 120 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06465329, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. The study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment? * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed? * How much of the study drug(s) are in the blood at a given time? * Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)?

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Cemiplimab
  • DRUG Platinum-based chemotherapy
  • DRUG REGN7075

Study Locations (20)

Tennessee

  • University of Tennessee Medical Center - Knoxville
  • Sarah Cannon Research Institute (SCRI) Oncology Partners - Nashville
  • Tennessee Oncology - Nashville

Michigan

  • Karmanos Cancer Institute - Detroit
  • Detroit Clinical Research Center - Farmington Hills

New Jersey

  • Morristown Medical Center - Morristown
  • Rutgers Cancer Institute of New Jersey - New Brunswick

Oregon

  • Providence Portland Medical Center - Portland
  • University Of Nebraska Medical Center - Portland

Minas Gerais

  • Instituto Mario Penna - Belo Horizonte
  • Instituto Sul Mineiro De Oncologia LTDA - Pouso Alegre

California

  • University of California Irvine - Orange

Illinois

  • Orchard Healthcare Research Inc. - Skokie

Rhode Island

  • Lifespan Cancer Institute - Providence

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-11-18
Est. Completion 2030-05-02
Phase Phase 2
Regeneron Pharmaceuticals

280 total trials

What NCT06465329 shows while recruiting

NCT06465329 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (82% lower).

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cemiplimab is the first listed.

NCT06465329 names 20 study sites across 14 states, led by Tennessee, Michigan, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06465329 about?

NCT06465329 is a clinical study titled "A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)". This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemi...

What is the current status of trial NCT06465329?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-11-18. Estimated completion is 2030-05-02.

What conditions does trial NCT06465329 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT06465329?

The interventions under investigation include: Cemiplimab (DRUG), Platinum-based chemotherapy (DRUG), REGN7075 (DRUG).

Who is sponsoring clinical trial NCT06465329?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06465329 being conducted?

This trial has 20 study locations across California, Illinois, Michigan, New Jersey, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06465329's enrollment target sits among peer trials

120 219th of 454 higher than 234 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06465329

Source: ClinicalTrials.gov NCT06465329, the US trial registry maintained by the National Library of Medicine. NCT06465329 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.